It is hypothesized that dual inhibitors of PDE4 and PDE7 may offer a therapeutic choice in HF with inflammation and exhibit a lower propensity to cause adverse side effects by PDE4 inhibitors. This evidence concerns the gene PDE4A and hydrops fetalis.